ArticleFrontiers in pharmacology2022
Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 21 citations in OpenAlex.
- Artificial Intelligence-Guided Prioritization and Experimental Evaluation of Synergistic Target Combinations for Breast Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Rethinking anti-cancer drug discovery: the evolution from polypharmacy to unified drug units.Cancer biology & medicine · 2026Article
- Evaluating the combined efficacy of Telisotuzumab Vedotin and artificial intelligence in the treatment of non-squamous non-small cell lung cancer: a narrative review focusing on pharmaceutical and technical insights.Frontiers in oncology · 2025Review
- Comprehensive applications of the artificial intelligence technology in new drug research and development.Health information science and systems · 2024Review
- Optimized models and deep learning methods for drug response prediction in cancer treatments: a review.PeerJ. Computer science · 2024Article
- Artificial intelligence-driven identification and mechanistic exploration of synergistic anti-breast cancer compound combinations fromFrontiers in pharmacology · 2024Article
- A general prediction model for compound-protein interactions based on deep learning.Frontiers in pharmacology · 2024Article
- Active metabolites combination therapies: towards the next paradigm for more efficient and more scientific Chinese medicine.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While synergistic drug combinations are more effective at fighting tumors with complex pathophysiology, preference compensating mechanisms, and drug resistance, the identification of novel synergistic drug combinations, especially complex higher-order combinations, remains challenging due to the size of combination space. Even though certain computational methods have been used to identify synergistic drug combinations
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.